Yourgene Health plc
("Yourgene" or the "Group" or the "Company")
Result of AGM
Manchester, UK - 29 September 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, announces that at the Annual General Meeting held yesterday, all ordinary resolutions were passed.
The voting results are now available on the 'Shareholder Communications' section of the Company's website: https://www.yourgene-health.com/investors/key-documents/shareholder-communications
|
Yourgene Health plc Lyn Rees, Chief Executive Officer |
Tel: +44 (0)161 669 8122 |
|||
|
Barry Hextall, Chief Financial Officer |
|
|||
|
Joanne Cross, Director of Marketing |
|
|||
|
|
|
|||
|
Cairn Financial Advisers LLP (NOMAD) |
Tel: +44 (0)20 7213 0880 |
|||
|
Liam Murray / James Caithie / Ludovico Lazzaretti |
|
|||
|
Singer Capital Markets (Joint Corporate Broker) |
Tel: +44 (0)20 7496 3000 |
|||
|
Aubrey Powell / Tom Salvesen / George Tzimas |
|
|||
|
|
|
|||
|
Stifel Nicolaus Europe Limited (Joint Corporate Broker) |
Tel: +44 (0)20 7710 7600 |
|||
|
Nicholas Moore / Matthew Blawat / Ben Maddison |
|
|||
|
|
|
|||
|
Walbrook PR Ltd (Media and Investor Relations) |
Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com |
|||
|
Paul McManus / Lianne Cawthorne |
Mob: 07980 541 893 / Mob: 07584 391 303 |
|||
|
|
|
|
|
|
About Yourgene Health plc
Yourgene Health is an international molecular diagnostics group which develops and commercialises genomic services and technologies. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and infectious diseases. The Group's flagship in vitro diagnostic products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests and DPYD genotyping.
Yourgene has a range of innovative DNA sample preparation platforms, powered by Ranger® Technology, the Yourgene LightBench® and Yourgene QS250, ideal for cell-free DNA applications in NIPT and oncology including liquid biopsy.
Yourgene Genomic Services is a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.
Yourgene Health is headquartered in Manchester, UK with facilities in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". Follow us on LinkedIn and Twitter.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
